Compare AGL & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGL | FEED |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Managed Health Care | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.3M |
| IPO Year | 2021 | N/A |
| Metric | AGL | FEED |
|---|---|---|
| Price | $80.72 | $0.92 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $55.68 | N/A |
| AVG Volume (30 Days) | ★ 555.5K | 395.7K |
| Earning Date | 05-06-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $30.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.91 |
| 52 Week High | $90.48 | $6.09 |
| Indicator | AGL | FEED |
|---|---|---|
| Relative Strength Index (RSI) | 78.35 | 28.39 |
| Support Level | $0.63 | N/A |
| Resistance Level | N/A | $1.54 |
| Average True Range (ATR) | 8.71 | 0.13 |
| MACD | 3.52 | -0.01 |
| Stochastic Oscillator | 87.14 | 10.66 |
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.